175 related articles for article (PubMed ID: 33939034)
1. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence.
Stoner MCD; Brown ER; Palanee-Phillips T; Mansoor LE; Tembo T; Nair G; Akello C; Seyama L; Jeenarain N; Naidoo L; Mgodi N; Hunidzarira P; Chitukuta M; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):4169-4179. PubMed ID: 33939034
[TBL] [Abstract][Full Text] [Related]
2. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
[TBL] [Abstract][Full Text] [Related]
3. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
[TBL] [Abstract][Full Text] [Related]
4. Male Partner Opinions of the Dapivirine Vaginal Ring Used During an Open-Label Extension HIV Prevention Trial in KwaZulu-Natal, South Africa.
Morar NS; Mansoor LE; Naidoo K; Katz AWK; Garcia M; Duma C; Precious Myeni NB; Tshbalala T; Naidoo S; Montgomery ET
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):127-133. PubMed ID: 36302179
[TBL] [Abstract][Full Text] [Related]
5. Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring.
Katz AWK; Balán IC; Reddy K; Etima J; Weber K; Tauya T; Atujuna M; Scheckter R; Ngure K; Soto-Torres L; Mgodi N; Palanee-Phillips T; Baeten JM; van der Straten A
AIDS Behav; 2022 Nov; 26(11):3607-3619. PubMed ID: 35536519
[TBL] [Abstract][Full Text] [Related]
6. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
[TBL] [Abstract][Full Text] [Related]
7. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
[TBL] [Abstract][Full Text] [Related]
8. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
[TBL] [Abstract][Full Text] [Related]
9. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
[TBL] [Abstract][Full Text] [Related]
10. Adolescent Girls and Young Women's Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis.
Young AM; Mancuso N; Atujuna M; Tenza S; Chitukuta M; Kemigisha D; Ngure K; van der Straten A; Garcia M; Szydlo D; Soto-Torres L; Roberts ST
AIDS Behav; 2023 Dec; 27(12):3941-3951. PubMed ID: 37392268
[TBL] [Abstract][Full Text] [Related]
11. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
[TBL] [Abstract][Full Text] [Related]
12. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
[TBL] [Abstract][Full Text] [Related]
13. Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa.
Gichane MW; Katz AWK; Ngure K; Scheckter R; Woeber K; Reddy K; Tauya T; Zimba C; Etima J; Mangxilana N; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):3847-3857. PubMed ID: 34009480
[TBL] [Abstract][Full Text] [Related]
14. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.
Garcia M; Luecke E; Mayo AJ; Scheckter R; Ndase P; Kiweewa FM; Kemigisha D; Musara P; Mansoor LE; Singh N; Woeber K; Morar NS; Jeenarain N; Gaffoor Z; Gondwe DK; Makala Y; Fleurs L; Reddy K; Palanee-Phillips T; Baeten JM; van der Straten A; Soto-Torres L; Torjesen K
BMC Public Health; 2021 Nov; 21(1):2041. PubMed ID: 34749675
[TBL] [Abstract][Full Text] [Related]
15. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
[TBL] [Abstract][Full Text] [Related]
16. Qualitative Perceptions of Dapivirine VR Adherence and Drug Level Feedback Following an Open-Label Extension Trial.
Naidoo K; Mansoor LE; Katz AWK; Garcia M; Kemigisha D; Morar NS; Zimba CC; Chitukuta M; Reddy K; Soto-Torres L; Naidoo S; Montgomery ET
J Acquir Immune Defic Syndr; 2021 Apr; 86(4):e90-e96. PubMed ID: 33278181
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Action of the Dapivirine Vaginal Ring as Understood by Women Participating in an Open Label Extension Study.
Naidoo K; T ME; Katz AW; Morgan G; Krishnaveni R; Lydia ST; Sarita N; Leila ME
AIDS Behav; 2023 Jan; 27(1):75-81. PubMed ID: 35672549
[TBL] [Abstract][Full Text] [Related]
18. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
19. Women's motivations for participating in the dapivirine vaginal ring open label extension study.
Naidoo K; Montgomery ET; Katz AWK; Garcia M; Naidoo S; Mansoor LE
AIDS Care; 2024 Mar; 36(3):326-342. PubMed ID: 37734338
[TBL] [Abstract][Full Text] [Related]
20. Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention.
Katz AWK; Mansoor LE; Tsidya M; Mathebula F; Singh D; Siva S; Akello C; Chitowa TH; Garcia M; Soto-Torres L; Montgomery ET
AIDS Behav; 2021 Dec; 25(12):3955-3966. PubMed ID: 34180041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
